# US 2011/0301170 A1 · Inhibitors of JNK

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0301170 A1
- Document ID: US20110301170A1
- Status: Published application
- Kind: A1
- Application number: 13/151,323
- Filed: 2011-06-02
- Published: 2011-12-08
- Earliest claimed: 2010-06-04
- Inventors: Leyi Gong; Yun-Chou Tan
- Web page: https://patentgrep.com/patent/US20110301170A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula I or pharmaceutically acceptable salts thereof, wherein: wherein m, n, p, q, X Y, Z, A, R1, R2, R3, R4, R5 and Y6 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity.

## Claims

### Claim 1

A compound of formula I
or pharmaceutically acceptable salts thereof,
wherein:
m is from 0 to 2;
n is from 0 to 2;
p is from 0 to 3;
q is from 0 to 2;
X is: CH; or N;
Y is: CRa; or N; wherein Ra is: hydrogen; C1-6alkyl; or —C(O)—NH2;
Z is: CRb; or N; wherein Rb is: hydrogen; C1-6alkyl; or halo-C1-6alkyl;
each R1 is independently : hydrogen; or C1-6alkyl;
A is CRb; or N;
each R2 is independently: C1-6alkyl; C1-6alkoxy; halo; halo-C1-6alkyl; or halo-C1-6alkoxy;
R3 is: hydrogen; halo; C1-6alkyl; halo-C1-6alkyl; halo-C1-6alkoxy; C1-6alkenyl; hydroxy-C1-6alkyl; C1-6alkylsulfonyl-C1-6alkoxy; tetrahydrothiophenyl-1,1-oxide-C1-6alkoxy; tetrahydrothiopyran-1,1-oxide-C1-6alkoxy; or piperidinyl optionally substituted with C1-6alkylsulfonyl;
each R4 is independently: C1-6alkyl; C1-6alkoxy; halo; halo-C1-6alkyl; or halo-C1-6alkoxy;
each R5 is independently: hydrogen; or C1-6alkyl; and
R6 is: hydrogen; C1-6alkyl; or halo-C1-6alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein m is 0.

### Claim 3 (depends on 1)

The compound of claim 1, wherein n is 0.

### Claim 4 (depends on 1)

The compound of claim 1, wherein p is 0.

### Claim 5 (depends on 1)

The compound of claim 1, wherein q is 0.

### Claim 6 (depends on 1)

The compound of claim 1, wherein X is CH.

### Claim 7 (depends on 1)

The compound of claim 1, wherein X is N.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Y is CRa.

### Claim 9 (depends on 1)

The compound of claim 1, wherein Y is N.

### Claim 10 (depends on 1)

The compound of claim 1, wherein Z is CRb.

### Claim 11 (depends on 1)

The compound of claim 1, wherein Z is N.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R3 is: halo; C1-6alkyl; halo-C1-6alkyl; halo-C1-6alkoxy; C1-6alkenyl; hydroxy-C1-6alkyl; C1-6alkylsulfonyl-C1-6alkoxy; tetrahydrothiophenyl-1,1-oxide-C1-6alkoxy; tetrahydrothiopyran-1,1-oxide-C1-6alkoxy; or piperidinyl optionally substituted with C1-6alkylsulfonyl.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R3 is: fluoro; methyl; trifluoromethyl; difluoromethoxy; 1-hydroxy-1-methyl-ethyl; isopropenyl; 3-methanesulfonyl-propoxy; 1,1-dioxo-tetrahydro-1λ6-thiophen-3-ylmethoxy; or 4-methanesulfonyl-piperidin-1-yl.

### Claim 14 (depends on 1)

The compound of claim 1, wherein said compound is selected from the group consisting of:
(5,6-Dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-(4-{4-[4-(3-methanesulfonyl-propoxy)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
(5,6-Dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
(5,6-Dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-(4-{4-[4-(1,1-dioxo-tetrahydro-1λ6-thiophen-3-ylmethoxy)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
(4-{4-[4-(3-Methanesulfonyl-propoxy)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(2-trifluoromethyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone;
1-{2-[4-(5,6-Dihydro-8H-imidazo[1,2-a]pyrazine-7-carbonyl)-cyclohexylamino]-pyrimidin-4-yl}-4-fluoro-1H-indole-3-carboxylic acid amide;
1-{2-[4-(5,6-Dihydro-8H-imidazo[1,2-a]pyrazine-7-carbonyl)-cyclohexylamino]-pyrimidin-4-yl}-5-fluoro-1H-indole-3-carboxylic acid amide;
(2-Ethyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-(4-{4-[4-(3-methanesulfonyl-propoxy)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
(4-{4-[4-(3-Methanesulfonyl-propoxy)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(3-methyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone;
(4-{4-[4-(1,1-Dioxo-tetrahydro-1λ6-thiophen-3-ylmethoxy)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(2-trifluoromethyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone;
{4-[4-(4-Isopropenyl-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(3-methyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone;
{4-[4-(4-Difluoromethoxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(3-methyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone;
(5,6-Dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-(4-{4-[4-(3-methanesulfonyl-propoxy)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
(4-{4-[4-(3-Methanesulfonyl-propoxy)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(2-trifluoromethyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone;
(4-{4-[4-(1,1-Dioxo-tetrahydro-1λ6-thiophen-3-ylmethoxy)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(2-trifluoromethyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone;
(5,6-Dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-(4-{4-[4-(1,1-dioxo-tetrahydro-1λ6-thiophen-3-ylmethoxy)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
(5,6-Dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-(4-{4-[4-(1-hydroxy-1-methyl-ethyl)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(3-trifluoromethyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-methanone;
(5,6-Dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
(4-{4-[4-(3-Methanesulfonyl-propoxy)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(3-trifluoromethyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-methanone;
(5,6-Dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-(4-{4-[4-(3-methanesulfonyl-propoxy)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
4-Fluoro-1-{2-[4-(3-trifluoromethyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)-cyclohexylamino]-pyrimidin-4-yl}-1H-indole-3-carboxylic acid amide;
1-{2-[4-(5,6-Dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)-cyclohexylamino]-pyrimidin-4-yl}-4-fluoro-1H-indole-3-carboxylic acid amide;
(4-{4-[4-(3-Methanesulfonyl-propoxy)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(3-methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-methanone;
(5,6-Dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-(4-{4-[4-(1,1-dioxo-tetrahydro-1λ6-thiophen-3-ylmethoxy)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
(5,6-Dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-{4-[4-(4-isopropenyl-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-methanone;
{4-[4-(4-Isopropenyl-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(3-methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-methanone;
{4-[4-(4-Difluoromethoxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-methanone;
{4-[4-(4-Difluoromethoxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(3-methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-methanone;
(5,6-Dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-{4-[4-(4-trifluoromethyl-indazol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-methanone;
(3-Methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-{4-[4-(4-trifluoromethyl-indazol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-methanone;
(5,6-Dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-(4-{4-[4-(1-hydroxy-1-methyl-ethyl)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
(4-{4-[4-(1-Hydroxy-1-methyl-ethyl)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(3-methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-methanone;
{4-[4-(4-Methyl-benzotriazol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(2-trifluoromethyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone;
(5,6-Dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-{4-[4-(4-methyl-benzotriazol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-methanone;
{4-[4-(4-Methyl-benzotriazol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(3-methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-methanone;
{4-[4-(4-Methyl-benzotriazol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(3-methyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone;
(5,6-Dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-{4-[4-(4-trifluoromethyl-benzotriazol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-methanone;
(5,6-Dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-(4-{4-[4-(1-hydroxy-1-methyl-ethyl)-benzotriazol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;
(4-{4-[4-(1-Hydroxy-1-methyl-ethyl)-benzotriazol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(3-methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-methanone;
{4-[4-(4-Isopropenyl-benzotriazol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(3-methyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone;
(4-{4-[4-(1-Hydroxy-1-methyl-ethyl)-benzotriazol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(3-methyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone;
(5,6-Dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-{4-[4-(8-trifluoromethyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-cyclohexyl}-methanone;
(3-Methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-{4-[4-(8-trifluoromethyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-cyclohexyl}-methanone;
{4-[4-(4-Difluoromethoxy-benzotriazol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-methanone;
{4-[4-(4-Difluoromethoxy-benzotriazol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(3-methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-methanone; and
{4-[4-(4-Difluoromethoxy-benzotriazol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-(3-methyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-methanone.

### Claim 16 (depends on 1)

A method of treating a JNK-mediated disorder in a subject having a JNK-mediated disorder, said method comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 17 (depends on 16)

The method of claim 16, wherein the arthritis is rheumatoid arthritis.

### Claim 18 (depends on 16)

The method of claim 16, wherein the JNK-mediated disorder is asthma.

### Claim 19 (depends on 16)

The method of claim 16, wherein the JNK-mediated disorder is diabetes.

### Claim 20 (depends on 1)

A composition comprising the compound of claim 1, admixed with at least one pharmaceutically acceptable carrier, excipient or diluent.
